Opioid Use Disorder Treatment Market By Product Type (Methadone, Buprenorphine [Sublingual Buprenorphine, Buprenorphine–Naloxone Combination, Weekly Extended-Release Buprenorphine Injection, Monthly Extended-Release Buprenorphine Injection], Naltrexone [Oral Naltrexone, Extended-Release Injectable Naltrexone], Adjunctive Withdrawal-Management Medications [Lofexidine, Clonidine, Other Supportive Medications]); By Application (Opioid Agonist Maintenance Treatment, Treatment Induction and Stabilization, Acute Opioid Withdrawal Management, Relapse Prevention, Post-Overdose Treatment Initiation, Hospital and Emergency Department-Initiated Treatment, Opioid Use Disorder Treatment During Pregnancy, Correctional and Post-Release Treatment, Long-Term Recovery and Retention Management); By End User (Opioid Treatment Programs, Hospitals and Emergency Departments, Outpatient Addiction Treatment Centers, Behavioral Health and Substance-Use Treatment Clinics, Primary Care and Office-Based Practices, Community Health Centers, Correctional Facilities, Rehabilitation Centers, Telehealth-Based OUD Treatment Providers, Retail and Specialty Pharmacies); By Route of Administration (Oral, Sublingual and Buccal, Injectable, Implantable); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Opioid Use Disorder Treatment Market: Low Medication Penetration and Long-Acting Buprenorphine Shift Revenue Toward Sustained Care

The Global Opioid Use Disorder Treatment Market was valued at USD 5.79 billion in 2025 and is projected to reach USD 9.49 billion by 2032, growing at a CAGR of 7.3%, according to Strategic Market Research.

 

The opioid use disorder treatment market is defined less by the availability of effective medicines than by the failure to move eligible patients into sustained medication-based care. Methadone, buprenorphine, and naltrexone are established treatments, but initiation, reimbursement, provider capacity, and retention remain inconsistent. Market growth therefore depends on converting untreated disease, behavioral-only care, overdose encounters, and short detoxification episodes into recurring medication and continuing clinical care.

 

A widely cited Global Burden of Disease analysis estimated that 40.5 million people were living with opioid dependence in 2019. This is a historical dependence estimate rather than a current measure of all non-medical opioid use, but it demonstrates that the treatment need extends well beyond North America.

 

A Large US Treatment Pool Remains Outside Medication-Based Care

The 2024 National Survey on Drug Use and Health estimated that 4.8 million Americans aged 12 or older had past-year opioid use disorder, equal to approximately 1.7% of the population. The total included 267,000 adolescents aged 12–17, 335,000 adults aged 18–25, and approximately 4.2 million adults aged 26 or older. Only 17.0%, or 818,000 people with active past-year OUD, received medications for opioid use disorder during 2024. A broader 2.2 million people received MOUD during the year, but that figure includes patients continuing successful treatment who may no longer have met the criteria for active past-year OUD.

Prescription-opioid exposure remains relevant to the future treatment pool. Approximately 8.6 million Americans reported misusing prescription opioids in 2023. The number declined to 7.6 million in 2024, although the latest survey does not include all illegally manufactured fentanyl use within its standard prescription-opioid misuse measure. The American Psychiatric Association also cites a broad estimate that 3%–12% of people treated with opioids for chronic pain develop addiction or harmful patterns of abuse. These figures connect the pain-treatment pathway with continuing demand for screening, early intervention, and OUD treatment, while avoiding the assumption that every patient receiving an opioid will develop OUD.

A separate CDC care-cascade analysis estimated that 9.37 million US adults needed OUD treatment in 2022, using a broader definition that included active disease and continuing treatment need. Around 55.2% received some form of treatment, but only 25.1%, or approximately 2.35 million adults, received medication. Another 30% received treatment without MOUD, while 42.7% did not believe that they needed treatment. The largest addressable opportunity therefore includes patients already interacting with rehabilitation, counseling, emergency, hospital, and criminal-justice systems without receiving medication.

US treatment demand must also be interpreted alongside changes in overdose mortality. In 2022, the country recorded 107,941 drug-overdose deaths. Opioids were involved in 81,806 deaths, including 73,838 involving synthetic opioids other than methadone, a category dominated by fentanyl and its analogues. By 2024, total overdose deaths had declined to 79,384, while opioid-involved deaths fell to 54,045 and synthetic-opioid deaths to 47,735. The decline is significant, but it does not indicate a proportional contraction in OUD prevalence or continuing-treatment demand.

Treatment uptake differs sharply by population. Among adults receiving OUD treatment, 51.0% of men received medication compared with 39.5% of women. MOUD utilization among treated patients ranged from 19.9% for adults aged 18–25 to 68.4% for those aged 35–49, before falling to 32.3% among adults aged 50 or older. These gaps indicate that national treatment growth will remain uneven across age, sex, race, insurance status, and care setting.

 

Medication Choice Creates Different Revenue and Access Models

The FDA-approved treatment base consists of methadone, buprenorphine, and naltrexone, but each follows a different distribution, reimbursement, and revenue pathway. Methadone remains closely tied to certified opioid treatment programs in the United States. Its frequent dispensing model supports long-duration treatment and recurring provider activity, but geographic concentration and regulatory requirements restrict access. In Europe, where public addiction-treatment systems are more established, methadone was used by 61% of the approximately 505,000 people receiving opioid agonist treatment in 2024, compared with 36% receiving buprenorphine-based medicines. Methadone therefore remains the volume leader in mature maintenance-treatment systems, although much of its demand is supplied through low-cost generics and publicly funded programs rather than premium branded products. The global methadone market was valued at approximately $300 million in 2022. The North American region accounts for roughly 60% of sales due to high opioid dependency rates and established treatment infrastructure. Europe follows with an estimated 25%, driven by government-funded addiction programs. Asia-Pacific holds around 10%, with growth influenced by expanding healthcare access in countries like China and India.

Sublingual buprenorphine supports the broadest office-based and telehealth treatment pathway. Generic availability limits branded pharmaceutical pricing, while prescription volume, pharmacy dispensing, clinical monitoring, behavioral support, and continuing follow-up create a large recurring-care segment. Indivior’s Suboxone Film illustrates the pressure on mature oral brands: the product faced four US generic competitors, and its share of the oral buprenorphine treatment category declined from more than 50% in 2018 to an average of 14.2% in 2025. Indivior ceased US sales-force promotion of Suboxone Film in 2020, and its 2025 annual filing states that settlement restrictions effectively prohibit US marketing of the product through 2032. These constraints are accelerating Indivior’s strategic shift from branded daily therapy toward long-acting buprenorphine.

Long-acting injectable buprenorphine changes the treatment economics more substantially. Weekly or monthly administration reduces dependence on daily adherence and creates a provider-administered treatment event, although adoption depends on insurance authorization, clinic capacity, product acquisition procedures, and continuity between inpatient and outpatient providers. Indivior reported USD 856 million in Sublocade net revenue in 2025, up 13% from USD 756 million in 2024. Sublocade accounted for 69% of the company’s USD 1.24 billion total net revenue, compared with 64% in 2024 and 58% in 2023. US Sublocade revenue reached USD 794 million, with dispensing-unit volume increasing 7%. The figures show that revenue is shifting toward long-acting formulations considerably faster than the diagnosed OUD population is expanding.

Extended-release naltrexone occupies a separate treatment position because patients generally must complete opioid withdrawal before initiation. This requirement can reduce conversion immediately after active opioid use or overdose, limiting its applicability relative to methadone and buprenorphine. Alkermes reported USD 467.9 million in Vivitrol net sales in 2025, up from USD 457.3 million in 2024, and projected 2026 sales of USD 460 million to USD 480 million. Vivitrol is approved for both alcohol dependence and the prevention of relapse to opioid dependence, so its reported revenue should not be classified entirely as OUD treatment revenue. Its comparatively stable outlook, against Sublocade’s double-digit growth, indicates a mature but durable injectable franchise with a narrower OUD initiation pathway.

The revenue profiles of the three medication pathways are therefore structurally different. Methadone generates high treatment volume through regulated and often publicly funded dispensing networks. Generic sublingual buprenorphine provides broad access but faces price competition, while branded oral products continue to lose share. Extended-release naltrexone supports a stable provider-administered segment but has a more restrictive initiation pathway. Long-acting buprenorphine is capturing the strongest pharmaceutical revenue growth because it combines recurring administration with higher revenue per treated patient and directly addresses missed doses, diversion risk, and treatment discontinuity.

 

Hospitals Are Becoming High-Value Treatment-Conversion Channels

Emergency departments and hospitals encounter patients at the point of overdose, withdrawal, infection, trauma, or other opioid-related complications, but medication initiation remains limited.

The 2025 START randomized clinical trial involving 325 hospitalized adults found that a dedicated addiction-consult service increased inpatient MOUD initiation from 26.7% under usual care to 57.3%. Linkage to post-discharge OUD care increased from 48.1% to 72.0%. The results demonstrate that hospital-based teams can more than double treatment initiation when medication management is combined with discharge planning and follow-up.

Hospital demand consequently extends beyond the medicine itself. Addiction specialists, care managers, peer navigators, bridge prescriptions, discharge pharmacies, referral systems, and outpatient follow-up are required to convert an acute encounter into continuing treatment. Without these services, patients may receive an initial dose but disengage before stabilization.

Retention has direct market relevance because long-duration treatment generates recurring medication, administration, monitoring, counseling, and care-management activity. Programs limited to initial prescribing capture less value than systems capable of maintaining patients through psychiatric illness, unstable housing, infectious disease, insurance changes, or transportation difficulties.

 

Long-Acting Buprenorphine Is Outgrowing the Broader Treatment Base

FDA approval of Brixadi in May 2023 introduced weekly and monthly extended-release buprenorphine options alongside the established monthly Sublocade franchise. Weekly administration provides greater flexibility during initiation or dose adjustment, while monthly administration is intended for patients already stabilized on buprenorphine.

US uptake accelerated between 2021 and 2024. A Rutgers-led analysis found major growth in long-acting injectable buprenorphine prescribing, but penetration varied from less than 1% of total buprenorphine prescribing in some states to nearly 13% in others. Pennsylvania, Louisiana, Alaska, and Ohio recorded relatively high utilization, with Medicaid design and prescribing by advanced-practice clinicians identified as important adoption factors.

Manufacturer performance confirms that revenue is shifting toward extended-release formulations faster than the underlying patient population is expanding. Indivior reported Sublocade net revenue of USD 232 million during the first quarter of 2026, up 32% from USD 176 million in the corresponding 2025 quarter. This growth reflects formulation conversion, increased treatment duration, and deeper provider penetration rather than an equivalent rise in OUD prevalence.

The World Health Organization reinforced this formulation category in April 2026 by adding a conditional recommendation for long-acting injectable buprenorphine. Methadone and oral buprenorphine retained strong recommendations, indicating that injectables will expand as an additional treatment option rather than replace established maintenance therapy.

 

Europe Provides Higher Coverage but Retains Country-Level Gaps

Approximately 505,000 people received opioid agonist treatment in the European Union during 2024. Methadone accounted for 61% of European opioid agonist treatment patients, buprenorphine-based medicines for 36%, and other agonists for approximately 3%.

Europe therefore has a more mature maintenance-treatment base than most regions. Methadone remains the volume leader, while buprenorphine competes through outpatient flexibility, lower supervision requirements, and extended-release delivery.

National policy remains decisive. Coverage differs considerably according to prescribing regulations, treatment capacity, public procurement, and reimbursement. Regional prevalence alone therefore provides a weak indicator of national commercial potential.

 

Global Burden Exceeds Near-Term Commercial Access

The 40.5 million global opioid-dependence estimate relates to 2017 and remains widely cited in the clinical literature. More recent WHO and UN data use a broader measure, estimating that approximately 60–61 million people engaged in non-medical opioid use during 2022–2023. Non-medical use is not equivalent to diagnosed opioid dependence, so these populations should not be combined into one prevalence estimate.

WHO estimates that more than 100,000 people die from opioid overdoses globally each year and calculated approximately 125,000 opioid-overdose deaths in 2019. WHO separately attributes around 450,000 of approximately 600,000 annual drug-related deaths to opioid use. The 450,000 figure includes the broader mortality attributable to opioid use and should not be presented as an opioid-overdose count.

Much of the global treatment need is not immediately accessible. Many countries lack trained prescribers, opioid agonist programs, controlled-medicine supply chains, reimbursement, and overdose-response infrastructure. Generic methadone and sublingual buprenorphine, government procurement, primary-care delivery, and community programs are likely to expand before premium long-acting injectables in lower-resource health systems.

 

Pipeline Value Is Concentrated in Delivery and Adjunctive Treatment

Pipeline development is targeting longer dosing intervals, withdrawal control, craving reduction, and protection against illicit opioids. Most novel mechanisms remain too early to challenge established maintenance therapy.

In June 2026, an NIH Investigational New Drug application for mitragynine, the principal psychoactive compound associated with kratom, took effect. The planned Phase I study will evaluate safety, tolerability, and pharmacology rather than establish treatment efficacy. Later development will depend on abuse liability, dose consistency, safety, and demonstrated advantages over existing MOUD.

GLP-1 receptor agonists, non-opioid withdrawal treatments, vaccines, and monoclonal antibodies are also being investigated. Their near-term role is more likely to be adjunctive because they do not yet match the clinical evidence or treatment infrastructure supporting methadone and buprenorphine.

The strongest near-term pipeline opportunity remains improved delivery of established medicines. Longer dosing intervals, easier initiation, and evidence in hospital, pregnancy, correctional, and unstable-patient settings address identifiable failures in adherence and treatment continuity with lower development risk than entirely new mechanisms.

 

Competitive Advantage Depends on Treatment Conversion and Retention

Generic methadone and sublingual buprenorphine will continue to provide the market’s volume base. Long-acting buprenorphine is capturing a growing share of pharmaceutical revenue because it increases revenue per treated patient and reduces daily-adherence requirements.

Hospitals, opioid treatment programs, community clinics, telehealth services, pharmacies, and public programs determine how much epidemiological need becomes treated demand. OUD prevalence defines the addressable population, but market value is created through medication initiation, reimbursement approval, continuing treatment, and retention.

The market’s central growth mechanism is therefore treatment conversion rather than rising overdose mortality. Health systems that move patients from prescription-opioid misuse, overdose, withdrawal, behavioral-only care, or interrupted treatment into sustained MOUD will determine the pace and distribution of future market expansion.

 

Global Opioid Use Disorder Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.79 Billion
Revenue Forecast in 2032	USD 9.49 Billion
Overall Growth Rate	CAGR of 7.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Route of Administration, By Geography
By Product Type	Methadone; Buprenorphine (Sublingual Buprenorphine, Buprenorphine–Naloxone Combination, Weekly Extended-Release Buprenorphine Injection, Monthly Extended-Release Buprenorphine Injection); Naltrexone (Oral Naltrexone, Extended-Release Injectable Naltrexone); Adjunctive Withdrawal-Management Medications (Lofexidine, Clonidine, Other Supportive Medications)
By Application	Opioid Agonist Maintenance Treatment; Treatment Induction and Stabilization; Acute Opioid Withdrawal Management; Relapse Prevention; Post-Overdose Treatment Initiation; Hospital and Emergency Department-Initiated Treatment; Opioid Use Disorder Treatment During Pregnancy; Correctional and Post-Release Treatment; Long-Term Recovery and Retention Management
By End User	Opioid Treatment Programs; Hospitals and Emergency Departments; Outpatient Addiction Treatment Centers; Behavioral Health and Substance-Use Treatment Clinics; Primary Care and Office-Based Practices; Community Health Centers; Correctional Facilities; Rehabilitation Centers; Telehealth-Based OUD Treatment Providers; Retail and Specialty Pharmacies
By Route of Administration	Oral; Sublingual and Buccal; Injectable; Implantable
By Region	North America; Europe; Asia-Pacific; Latin America; Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Netherlands, China, India, Japan, Australia, South Korea, Brazil, Argentina, Colombia, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising prevalence of opioid use disorder and increasing demand for evidence-based addiction treatment solutions. • Growing adoption of medication-assisted treatment programs across healthcare systems and community care settings. • Expansion of telehealth-enabled addiction services and improved access to long-term recovery management.
Customization Option	Available upon request